Integrated Wealth Concepts LLC Reduces Stake in Johnson & Johnson $JNJ

Key Points

• Integrated Wealth Concepts LLC has decreased its stake in Johnson & Johnson by 5.4%, now owning 102,599 shares valued at approximately $17 million.
• Other institutional investors have modified their holdings, with significant increases from firms like Lantz Financial LLC and Apexium Financial LP, reflecting ongoing interest in Johnson & Johnson's stock.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing an annualized dividend yield of 2.9%.

Integrated Wealth Concepts LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.4% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 102,599 shares of the company's stock after selling 5,874 shares during the period. Integrated Wealth Concepts LLC's holdings in Johnson & Johnson were worth $17,015,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lantz Financial LLC raised its holdings in shares of Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after acquiring an additional 377 shares in the last quarter. Apexium Financial LP raised its holdings in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC raised its holdings in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares in the last quarter. State of Wyoming raised its holdings in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after buying an additional 10,279 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after buying an additional 4,816 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ opened at $178.64 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The stock has a market capitalization of $430.23 billion, a PE ratio of 19.11, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The stock's 50 day moving average price is $168.06 and its 200-day moving average price is $160.60.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Bank of America raised their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Finally, Guggenheim restated a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.